

Rizatriptan Orally Disintegrating Formulation

Version 2.4 Revision Date: 10.10.2020 SDS Number: 818379-00010 Date of last issue: 23.03.2020
Date of first issue: 22.07.2016

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Rizatriptan Orally Disintegrating Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION**Manufacture, Storage and Import of Hazardous Chemicals Rules 1989****Classification**

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Skin corrosion/irritation : Category 3

Skin sensitisation : Category 1

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Cardio-vascular system)

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H316 Causes mild skin irritation.
H317 May cause an allergic skin reaction.
H373 May cause damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.

Precautionary statements :

Prevention:

P260 Do not breathe dust.

P272 Contaminated work clothing should not be allowed out of

Rizatriptan Orally Disintegrating Formulation

Version 2.4 Revision Date: 10.10.2020 SDS Number: 818379-00010 Date of last issue: 23.03.2020
Date of first issue: 22.07.2016

the workplace.
P280 Wear protective gloves.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.
P319 Get medical help if you feel unwell.
P333 + P317 If skin irritation or rash occurs: Get medical help.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 - < 20
Peppermint oil	8006-90-4	>= 2.5 - < 5
Starch	9005-25-8	>= 1 - < 5
Rizatriptan	145202-66-0	>= 1 - < 3

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Causes mild skin irritation.
May cause an allergic skin reaction.
May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : Dust contact with the eyes can lead to mechanical irritation.
First Aid responders should pay attention to self-protection,

Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	10.10.2020	818379-00010	Date of first issue: 22.07.2016

Notes to physician : and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020
2.4 10.10.2020 818379-00010 Date of first issue: 22.07.2016

7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
Starch	9005-25-8	TWA	10 mg/m ³	ACGIH
Rizatriptan	145202-66-0	TWA	10 µg/m ³ (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type

Rizatriptan Orally Disintegrating Formulation

Version 2.4 Revision Date: 10.10.2020 SDS Number: 818379-00010 Date of last issue: 23.03.2020
Date of first issue: 22.07.2016

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

SAFETY DATA SHEET



Rizatriptan Orally Disintegrating Formulation



Version 2.4 Revision Date: 10.10.2020 SDS Number: 818379-00010 Date of last issue: 23.03.2020
Date of first issue: 22.07.2016

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact

Rizatriptan Orally Disintegrating Formulation

Version 2.4 Revision Date: 10.10.2020 SDS Number: 818379-00010 Date of last issue: 23.03.2020
Date of first issue: 22.07.2016

Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Peppermint oil:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Rizatriptan:

Acute oral toxicity : LD50 (Rat): 2,227 mg/kg

LD50 (Mouse): 700 - 1,631 mg/kg

Skin corrosion/irritation

Causes mild skin irritation.

Components:**Peppermint oil:**

Species : Rabbit
Result : Skin irritation
Remarks : Based on data from similar materials

Rizatriptan:

Species : Rabbit
Result : No skin irritation

Rizatriptan Orally Disintegrating Formulation

Version 2.4 Revision Date: 10.10.2020 SDS Number: 818379-00010 Date of last issue: 23.03.2020
Date of first issue: 22.07.2016

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Peppermint oil:**

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Remarks : Based on data from similar materials

Starch:

Species : Rabbit
Result : No eye irritation

Rizatriptan:

Species : Bovine cornea
Remarks : Moderate eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:**Peppermint oil:**

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : positive
Remarks : Based on data from similar materials

Assessment : Probability or evidence of skin sensitisation in humans

Starch:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Rizatriptan:

Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Assessment : Does not cause skin sensitisation.
Result : negative

Rizatriptan Orally Disintegrating Formulation

Version 2.4 Revision Date: 10.10.2020 SDS Number: 818379-00010 Date of last issue: 23.03.2020
Date of first issue: 22.07.2016

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Rizatriptan:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Alkaline elution assay
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	10.10.2020	818379-00010	Date of first issue: 22.07.2016

Rizatriptan:

Species : Mouse
 Application Route : Oral
 Exposure time : 100 weeks
 NOAEL : 125 mg/kg body weight
 Result : negative

Species : Rat
 Application Route : Oral
 Exposure time : 106 weeks
 NOAEL : 106 mg/kg body weight
 Result : negative

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 Result: negative

Rizatriptan:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat, female
 Application Route: Oral
 Fertility: LOAEL: 100 mg/kg body weight
 Symptoms: altered estrus cycles
 Result: No effects on fertility and early embryonic development were detected.

Test Type: Fertility/early embryonic development
 Species: Rat, male
 Application Route: Oral
 Fertility: NOAEL: 250 mg/kg body weight
 Result: No effects on fertility and early embryonic development were detected.

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: LOAEL: 10 mg/kg body weight
 Result: No teratogenic effects, Embryo-foetal toxicity

Test Type: Embryo-foetal development
 Species: Rabbit
 Application Route: Oral

Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	10.10.2020	818379-00010	Date of first issue: 22.07.2016

Developmental Toxicity: LOAEL: 100 mg/kg body weight
 Result: No teratogenic effects, Embryo-foetal toxicity
 Remarks: The effects were seen only at maternally toxic doses.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:**Rizatriptan:**

Assessment : May cause drowsiness or dizziness.

STOT - repeated exposure

May cause damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.

Components:**Rizatriptan:**

Target Organs : Cardio-vascular system
 Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Cellulose:**

Species : Rat
 NOAEL : $\geq 9,000$ mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Starch:

Species : Rat
 NOAEL : $\geq 2,000$ mg/kg
 Application Route : Skin contact
 Exposure time : 28 Days
 Method : OECD Test Guideline 410

Rizatriptan:

Species : Rat
 LOAEL : 1 mg/kg
 Application Route : Oral
 Exposure time : 14 Weeks
 Symptoms : Dilatation of the pupil, Increased pulse rate, Redness

Species : Dog
 LOAEL : 0.05 mg/kg

Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	10.10.2020	818379-00010	Date of first issue: 22.07.2016

Application Route	:	Intravenous
Exposure time	:	2 Weeks
Symptoms	:	Dilatation of the pupil, Increased pulse rate, Redness
Species	:	Dog
LOAEL	:	0.2 mg/kg
Application Route	:	Oral
Exposure time	:	1 yr
Symptoms	:	Dilatation of the pupil

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Rizatriptan:**

Ingestion	:	Target Organs: Cardio-vascular system Symptoms: asthenia, Fatigue, Pain, Dizziness, Weakness, Drowsiness
-----------	---	---

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	--

Peppermint oil:

Toxicity to fish	:	LL50 (Danio rerio (zebra fish)): > 10 - 100 mg/l Exposure time: 96 h Remarks: Based on data from similar materials
------------------	---	--

Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 10 - 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
---	---	--

Toxicity to algae/aquatic plants	:	EL50 (Desmodesmus subspicatus (green algae)): > 10 - 100 mg/l Exposure time: 72 h Remarks: Based on data from similar materials
----------------------------------	---	---

Toxicity to microorganisms	:	EC10: 51 mg/l Exposure time: 3 h Remarks: Based on data from similar materials
----------------------------	---	--

Rizatriptan:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l
------------------	---	---

Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	10.10.2020	818379-00010	Date of first issue: 22.07.2016

- Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,000 mg/l
Exposure time: 48 h
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 48 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
- NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
- Toxicity to fish (Chronic toxicity) : NOEC: 9.6 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 110 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Peppermint oil:

Biodegradability : Result: Readily biodegradable.
Remarks: Based on data from similar materials

Rizatriptan:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 13 d
Method: OECD Test Guideline 314

Rizatriptan Orally Disintegrating Formulation

Version 2.4 Revision Date: 10.10.2020 SDS Number: 818379-00010 Date of last issue: 23.03.2020
Date of first issue: 22.07.2016

Bioaccumulative potential**Components:****Peppermint oil:**

Partition coefficient: n-octanol/water : log Pow: > 4
Remarks: Based on data from similar materials

Rizatriptan:

Partition coefficient: n-octanol/water : log Pow: -0.649

Mobility in soil**Components:****Rizatriptan:**

Distribution among environmental compartments : log Koc: 3.83
Method: OECD Test Guideline 106

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

SAFETY DATA SHEET



Rizatriptan Orally Disintegrating Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	10.10.2020	818379-00010	Date of first issue: 22.07.2016

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be

SAFETY DATA SHEET



Rizatriptan Orally Disintegrating Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	10.10.2020	818379-00010	Date of first issue: 22.07.2016

considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN